However, tumor–to–contralateral breast ratios were significantly (P < 0.05, Mann–Whitney test) higher for HER2-positive lesions at 2 and 4 h in 1,000-μg and 2,000-μg cohorts, and at 2, 4, and 6 h in the 3,000-μg cohort (Fig. 5). This evidence concerns the gene ERBB2 and neoplasm.